NNC0537-1482

Phase 1Small molecule

Novo Nordisk

NNC0537-1482 is one of 83 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney DiseaseNot yet recruiting

Heart FailureRecruiting

Chronic Kidney DiseasePhase 1

Not yet recruiting

Heart FailurePhase 1

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

2 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Heart Failure

NCT07218627

Q3 2027

Phase 1Not yet recruiting

Chronic Kidney Disease

NCT07808788

Clinical

Trials by Indication[1]

Heart Failure2 trials

A Randomised, Placebo-controlled, Double-blinded Phase 1b Study Investigating Safety, Tolerability, Pharmacokinetics and Effects on Biomarkers From Multiple Ascending Doses of NNC0537-1482 in Participants With Heart Failure

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07218627·36 enrolled

A First-in-human Randomised, Placebo-controlled and Double-blinded Single Ascending Dose Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administrations of NNC0537-1482 in Healthy Participants.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06625307·31 enrolled

Chronic Kidney Disease1 trial

Investigation of Pharmacokinetics of a Single Subcutaneous Dose of NNC0537-1482 in Participants With Various Degrees of Renal Function

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07808788·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NNC0537-1482. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NNC0537-1482 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NNC0537-1482. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novo Nordisk

NNC0537-1482

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Heart Failure2 trials

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News